AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00688779
Drug: AZD8848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for nasal spray,solution 60 mg/g
Trial: NCT00688779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00994292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00300586
Drug: observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observation, second line chemotherapy if progression
Trial: NCT04464512
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV buprenorphine plus IV sufentanil treatment group.
Trial: NCT01103284
Drug: DiaPep277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg dose in 0.5 mL of solution
Trial: NCT01103284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months
Trial: NCT04527250
Drug: ASC41
RxNorm normalized name: Ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASC41,1mg/table;5mg/table
Trial: NCT04527250
Drug: ASC41 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC41 placebo,1mg/table;5mg/table
Trial: NCT03404167
Drug: AZD0914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
Trial: NCT00705081
Drug: statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00094627
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment - 6 weeks
Trial: NCT04370600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
Trial: NCT00448357
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m\^2 on days +1, +3 and +6
Trial: NCT04398914
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician decided chemotherapy for 0-4 cycles.
Trial: NCT03520569
Drug: Dextrose 20% solution
RxNorm normalized name: Dextrose 20% Solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We are using dextrose to maintain glycemia level
Trial: NCT00361244
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
Trial: NCT03202550
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral pills
Trial: NCT04405388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally as capsule (same size and weight as Spermidine capula)
Trial: NCT04405388
Drug: Spermidine
RxNorm normalized name: SPERMIDINE
DrugBank: Spermidine (DB03566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermidine will be given orally as capsule (4mg/day)
Trial: NCT04981561
Drug: GATE-251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of GATE-251
Trial: NCT04981561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03309605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04162314
Drug: Beta-1,3/1,6-D-Glucan Ganoderma lucidum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
Trial: NCT04162314
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos
Trial: NCT00394472
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02201082
Drug: Amikacin nebulization
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00882388
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg bid \* 7 days
Trial: NCT00882388
Drug: aspirin + celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
Trial: NCT00882388
Drug: aspirin + clopidogrel + celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
Trial: NCT03197935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to atezolizumab was administered as per schedule described in respective arm.
Trial: NCT03197935
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin was administered as per schedule described in the arms.
Trial: NCT03197935
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered as per schedule described in the arms.
Trial: NCT03990688
Drug: AK3280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Trial: NCT03990688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Trial: NCT01137812
Drug: Sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Trial: NCT02197104
Drug: citocoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
Trial: NCT01783015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept placebo once-weekly
Trial: NCT00873756
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT02389348
Drug: DSM265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of DSM265
Trial: NCT03886233
Drug: Corticosteroid Series
RxNorm normalized name: Corticosteroid series
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
Trial: NCT03226392
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 once daily
Trial: NCT03226392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT00661219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
Trial: NCT01972178
Drug: PRC-4016
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01972178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00076609
Drug: PHY906
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00076609
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03410537
Drug: Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03410537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01975480
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00732693
Drug: Ethinylestradiol / Norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days
Trial: NCT00732693
Drug: Estradiol / Progesterone
RxNorm normalized name: estradiol / progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
Trial: NCT01960842
Drug: Levodopa-carbidopa intestinal gel
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
Trial: NCT03648970
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant will be given pravastatin 2 x 20 mg per oral daily
Trial: NCT02002208
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CRTH2 antagonist
Trial: NCT03128164
Drug: HMPL-689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
Trial: NCT01406431
Drug: Livalo® fixed combination drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livalo® fixed combination drug(1 tablet)
Trial: NCT03865680
Drug: CPP-ACP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
Trial: NCT01691742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
Trial: NCT01691742
Drug: Rescue Laxative
RxNorm normalized name: Pore Rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
Trial: NCT02943720
Drug: AllerT
RxNorm normalized name: AllerTan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
Trial: NCT02943720
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02734446
Drug: Reuterin D3 drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 drops/day for 3 months
Trial: NCT04025307
Drug: bacTRL-IL-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
Trial: NCT01362374
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
Trial: NCT03791476
Drug: rhC1INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase inhibitor
Trial: NCT03472469
Drug: Acetaminophen IV/PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1g IV/PO every 6 hours
Trial: NCT03472469
Drug: Acetaminophen PO
RxNorm normalized name: ACETAMINOPHEN POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1g PO every 6 hours
Trial: NCT03472469
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 30mg IV once
Trial: NCT03472469
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg PO every 12 hours
Trial: NCT03472469
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
Trial: NCT03472469
Drug: Regional anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional anesthesia
Trial: NCT02402543
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02402543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02826031
Drug: DICL-SR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02843386
Drug: Adjuvant chemotherapy by Fotemustin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21.
Trial: NCT01342146
Drug: Jintropin AQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg/wk, once a day for 25 weeks
Trial: NCT01741701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03251820
Drug: corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will be subjected to a one month course of steroids and then re-evaluated
Trial: NCT00927186
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.
Trial: NCT03108027
Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Trial: NCT03108027
Drug: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Trial: NCT03108027
Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (morning dose) and placebo (evening dose)
Trial: NCT01727973
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab. Doxycycline 50 mg PO per day for 12 weeks
Trial: NCT01750281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three placebo capsules will be administered orally uninterrupted twice daily.
Trial: NCT01421134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02765971
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C received 500 cc of normal saline, Intravenous fluid
Trial: NCT02306785
Drug: TP05 Coating E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One radio-labelled tablet given to subjects
Trial: NCT02306785
Drug: TP05 Coating H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One radio-labelled tablet given to subjects
Trial: NCT03394807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection to Transversus abdominis plane and rectus sheath
Trial: NCT01104298
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
Trial: NCT02663570
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01619683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule per day, oral
Trial: NCT01009242
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Individual stable doses of methotrexate.
Trial: NCT04517799
Drug: placebo oral solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change.
Trial: NCT01290731
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg capsule once daily for 12 weeks
Trial: NCT00601107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01271660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering
Trial: NCT01910090
Drug: FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET
RxNorm normalized name: flurbiprofen 100 MG
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MULTI-LAYER TABLET
Trial: NCT01910090
Drug: ANTADYS® 100 mg, PEPCID® 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
Trial: NCT01730209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00262808
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00262808
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00933374
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
Trial: NCT03119194
Drug: [14C]-BIA 9-1067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 100 mg capsule, Oral
Trial: NCT01181128
Drug: Advate®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02060149
Drug: C/S plus minocycline.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
Trial: NCT02060149
Drug: nebulization with pH 7.4 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
Trial: NCT02060149
Drug: nebulization with pH 7.8 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
Trial: NCT02060149
Drug: No nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nebulization will be given to the patients.
Trial: NCT01330589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active placebo for 7 days: PO/TID
Trial: NCT02532790
Drug: ACEI
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2-0.3mg/kg/d
Trial: NCT01858090
Drug: Control Group Chirocaine
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
Trial: NCT01858090
Drug: Group Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01858090
Drug: Group sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01858090
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: as additional analgesic among cases in which VAS\>3(Postoperatively)
Trial: NCT00268996
Drug: SB-480848 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is available as enteric-coated, free-base micronized tablet
Trial: NCT00533845
Drug: On-Q Pain Pump
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
Trial: NCT03676933
Drug: DS107E
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03676933
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no